Amyloid-β-targeting immunotherapies for Alzheimer's disease
Y Jin, Q Du, M Song, R Kang, J Zhou, H Zhang… - Journal of Controlled …, 2024 - Elsevier
Recent advances in clinical passive immunotherapy have provided compelling evidence
that eliminating amyloid-β (Aβ) slows cognitive decline in Alzheimer's disease (AD) …
that eliminating amyloid-β (Aβ) slows cognitive decline in Alzheimer's disease (AD) …
Revolutionizing Alzheimer's Treatment: Harnessing Human Serum Albumin for Targeted Drug Delivery and Therapy Advancements
Alzheimer's disease (AD) is a neurodegenerative disorder initiated by amyloid-beta (Aβ)
accumulation, leading to impaired cognitive function. Several delivery approaches have …
accumulation, leading to impaired cognitive function. Several delivery approaches have …
Poloxamer®s anchored with TAT enhance blood–brain barrier penetration of carbamazepine for the treatment of epilepsy: an in vivo study
Carbamazepine is a pharmacological medication commonly prescribed to treat epilepsy.
Dose adjustments, poor bioavailability, and prolonged side effects present significant …
Dose adjustments, poor bioavailability, and prolonged side effects present significant …
Preclinical, clinical, and patented nanodrug delivery systems
SS Ningthoujam - Advances in Nanotechnology-Based Drug Delivery …, 2022 - Elsevier
The second half of the last century has seen a tremendous advancement in the medical and
pharmaceutical sectors with special attention on development of biopharmaceutics and …
pharmaceutical sectors with special attention on development of biopharmaceutics and …